1 / 10

Paul J. Larsen, Esq. CHPA Associate General Counsel & Secretary (Speaker)

Paul J. Larsen, Esq. CHPA Associate General Counsel & Secretary (Speaker). FDA Public Meeting – Proposed Changes to the National Drug Code (NDC) Number System December 11, 2006. Key Points. CHPA supports the development of an interactive, electronic system Potential benefits include –

belva
Download Presentation

Paul J. Larsen, Esq. CHPA Associate General Counsel & Secretary (Speaker)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Paul J. Larsen, Esq.CHPA Associate General Counsel & Secretary(Speaker) FDA Public Meeting – Proposed Changes to the National Drug Code (NDC) Number System December 11, 2006

  2. Key Points • CHPA supports the development of an interactive, electronic system • Potential benefits include – • Increased efficiency • Detection/prevention of errors and omissions • CHPA supports the existing NDC number system • CHPA recommendations • Adoption of a stepwise approach • Issuance of draft guidance and technical specifications • CHPA would like to work with FDA

  3. Benefits of the Existing NDC Number System • The current system affords needed flexibility • No pre-market review by FDA needed for OTC monograph drugs • Timely consumer access • Early assignment of NDC numbers • Trade channel requirements • Short-term promotional SKUs

  4. Benefits of the Existing NDC Number System • Avoid confusion and delays in case of product changes • Changes after the request for an NDC number is submitted • Multiple NDC numbers and requests • Changes after the product has an NDC number or is in the marketplace • Internal records • Manufacturing and control documents • Embedded UPC • New labels

  5. Benefits of the Existing NDC Number System • No need for inactive ingredient information in the existing NDC number system • Changes in inactive ingredient information can occur regularly for any number of reasons • Avoids confusion and delays which would occur if multiple NDC numbers had to be requested and assigned for the same product • Over-inclusive inactive ingredient labeling is allowed • Existing regulatory and related requirements are adequate

  6. Need for revision of the “appropriate NDC number” • Definition of “manufacturing” • Four functional types • “Specification developers” not covered under this definition • Unable to obtain NDC number • Contract manufacturer “forcibly” delegated this authority • CHPA encourages FDA to revise the proposed definition of “manufacturer” • To include specification developers

  7. Extend Timeframe for Reviewing and Updating Information for Listed Drugs Beyond 9 Months • Proposed timeframe is inadequate because – • Many products affected • Complexity of the proposal’s NDC number requirements • Products with multiple inactive ingredient combinations • Information entered by FDA into the drug listing database is itself not up-to-date

  8. Human-readable NDC Number on the Label • Concur with the Eastern Research Group findings • Space on the label concerns • Allow the use of “N” or “NDC” • Requiring the NDC number on secondary packaging • May create additional burdens for labeling of 2-in-1s

  9. Conclusion • CHPA supports an interactive, electronic system • Utilizes current NDC number system • Would serve FDA, the regulated industry, and the American consumer • Stepwise approach coupled with draft guidance and technical specifications • Look forward to working together

  10. Contact Information • Paul J. Larsen, Esq. CHPA Associate General Counsel & Secretary (202) 429-9260 plarsen@chpa-info.org Thank you, FDA

More Related